Welcome to our dedicated page for Tenet Healthcare SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Tenet Healthcare’s disclosures can feel like triaging a busy emergency room—hundreds of pages, three operating segments, and intricate Medicare rules pack every document. Whether you need Tenet Healthcare insider trading Form 4 transactions or the cash-flow detail buried in the Tenet Healthcare quarterly earnings report 10-Q filing, raw EDGAR text alone slows decisions.
Stock Titan’s AI quickly converts that overload into plain language. Our engine delivers Tenet Healthcare SEC filings explained simply, highlighting hospital occupancy swings, ambulatory surgery center margins, and Conifer Health Solutions revenue trends. Get push alerts for Tenet Healthcare Form 4 insider transactions real-time, one-click access to management’s risk commentary, and contextual charts that transform numbers into insight.
Use cases investors rely on:
- Compare segment EBITDAR across periods with Tenet Healthcare earnings report filing analysis.
- Answer board questions by understanding Tenet Healthcare SEC documents with AI instead of skimming 300 pages.
- Monitor sentiment via Tenet Healthcare executive stock transactions Form 4 before earnings calls.
The platform covers every form in real time. The Tenet Healthcare annual report 10-K simplified section surfaces payer-mix tables and litigation reserves; the Tenet Healthcare proxy statement executive compensation view breaks down incentive targets; and Tenet Healthcare 8-K material events explained flags sudden divestitures or ASC acquisitions within minutes. From first-read AI summaries to full PDF text, every filing is one search away—so you can focus on diagnosing value, not decoding jargon.
Tenet Healthcare (THC): Insider stock sale disclosed. Principal Accounting Officer R. Scott Ramsey reported open-market sales of common stock on 11/06/2025. Transactions included 8,056 shares at a weighted average price of $204.75 (sold across $204.21–$205.13) and 5,066 shares at a weighted average price of $205.62 (sold across $205.21–$206.14), plus 200 shares at $206.51. After these sales, the table shows beneficial ownership of common stock at 0 shares. The filing lists transaction code “S” for sales and notes weighted-average pricing with details available upon request.
Tenet Healthcare (THC) director Tammy Romo reported an open market sale of company stock. On 11/05/2025, she sold 645 shares of common stock at $205.20 per share, according to a Form 4 insider filing. After this transaction, she directly owns 34,866 shares of Tenet Healthcare common stock.
Tenet Healthcare (THC) filed a Form 144 indicating an intended sale of 13,322 shares of common stock through Fidelity Brokerage Services LLC on or about 11/06/2025, to be sold on the NYSE. The filing lists an aggregate market value of $2,732,412.25 for the proposed sale.
The shares reflect restricted stock that vested on multiple dates and were received as compensation from the issuer. Shares outstanding were 87,885,000; this is a baseline figure, not the amount being sold.
Tenet Healthcare (THC) director Tammy Romo reported open‑market sales of 26,855 shares on November 3–4, 2025. Trades occurred in multiple transactions within a per‑share range of $200.00 to $204.93, with weighted‑average prices disclosed for each tranche.
Following these transactions, Romo beneficially owns 35,511 shares, held directly. The filing lists tranches of 8,654, 5,945, 500, 11,410 and 346 shares at weighted‑average prices of $200.43, $201.23, $202.27, $204.04 and $204.93, respectively.
Tenet Healthcare Corporation entered a new senior secured asset‑based revolving credit facility of up to $1.9 billion, including a $200 million sub‑facility for letters of credit. Borrowing availability is tied to a borrowing base of eligible accounts receivable, inventory and Medicaid supplemental payments. The facility is guaranteed by certain domestic wholly owned hospital subsidiaries and secured by a first‑priority lien on accounts receivable and inventory.
Loans bear interest at a base rate plus 0.25%–0.50% or SOFR/EURIBOR plus 1.25%–1.50%, with a 0.25% commitment fee on undrawn commitments. It terminates on November 4, 2030 or earlier upon specified springing maturities tied to certain senior notes, subject to stated conditions. Tenet also amended and extended its separate $200 million letter of credit facility to November 4, 2030, with an unused fee of 0.25% and a 1.25% fee on issued but undrawn letters; unreimbursed drawings accrue at base rate plus 0.25%.
Tenet Healthcare (THC): Tammy N. Romo filed a Form 144 notice to sell up to 645 shares of Common stock, with an aggregate market value of $132,350.78. The planned sale is listed for 11/05/2025 on the NYSE via Fidelity Brokerage Services LLC.
The 645 shares were acquired on 05/08/2018 through restricted stock vesting as compensation. Recent sales by this holder during the past three months include 15,099 shares on 11/03/2025 for gross proceeds of
Shares outstanding are 87,885,000. This notice reflects a proposed sale under Rule 144; proceeds relate to the selling holder’s transactions.
Tenet Healthcare (THC): Form 144 notice of proposed sale
A holder of Tenet Healthcare common stock filed a Form 144 to sell up to 11,756 shares of common stock, with an aggregate market value of $2,399,032.11. The proposed sale is noted for 11/04/2025 on the NYSE through Fidelity Brokerage Services LLC.
Tenet Healthcare had 87,885,000 shares outstanding. The shares to be sold were acquired via restricted stock vesting in two tranches: 939 shares on 05/04/2021 and 10,817 shares on 05/03/2022. In the past three months, a sale of 15,099 shares on 11/03/2025 generated gross proceeds of $3,031,952.87.
Tenet Healthcare (THC) announced private offerings of $1.5 billion of 5.500% senior secured first lien notes due 2032 and an upsized $0.75 billion of 6.000% senior notes due 2033, with closings expected on November 18, 2025, subject to customary conditions. The first lien notes will be guaranteed by certain subsidiaries and secured on a first-lien basis; the senior notes are unsecured and rank pari passu with Tenet’s existing senior unsecured obligations.
The company plans to use net proceeds, together with cash on hand, to redeem all $1.5 billion of its 6.250% senior secured second lien notes due February 2027 and to partially redeem $0.75 billion of its 6.125% senior notes due October 2028. Tenet issued conditional redemption notices for both series, with redemptions scheduled for November 19, 2025. The transaction shifts maturities to 2032/2033 and lowers stated coupons on the refinanced debt.
Form 144 filed for a proposed sale of 15,099 common shares. The notice lists an aggregate market value of $3,031,952.87, with an approximate sale date of 11/03/2025. The broker is Fidelity Brokerage Services LLC, and the shares are listed on the NYSE.
The shares to be sold were acquired through restricted stock vesting: 11,139 shares on 05/29/2023 and 3,960 shares on 05/07/2024, recorded as compensation. The table also notes 87,885,000 shares outstanding; this is a baseline figure, not the amount being sold.
Tenet Healthcare (THC) reported an insider transaction by a director. On 10/29/2025, the director sold 2,500 shares of common stock at $208.43 per share. After this sale, the director beneficially owns 8,792 shares, held directly.
The filing lists the reporting person as Richard W. Fisher, with the form signed by attorney-in-fact Chad J. Wiener on 10/31/2025.
FAQ
What is the current stock price of Tenet Healthcare (THC)?
What is the market cap of Tenet Healthcare (THC)?
